These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 29502488

  • 21. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C, Mehra R, Sharma R, Chib R, Wazir P, Nargotra A, Khan IA.
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [Abstract] [Full Text] [Related]

  • 22. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
    Nam KW, Jang WS, Jyoti MA, Kim S, Lee BE, Song HY.
    Phytomedicine; 2016 May 15; 23(5):578-82. PubMed ID: 27064017
    [Abstract] [Full Text] [Related]

  • 23. Discovery of novel acetohydroxyacid synthase inhibitors as active agents against Mycobacterium tuberculosis by virtual screening and bioassay.
    Wang D, Zhu X, Cui C, Dong M, Jiang H, Li Z, Liu Z, Zhu W, Wang JG.
    J Chem Inf Model; 2013 Feb 25; 53(2):343-53. PubMed ID: 23316686
    [Abstract] [Full Text] [Related]

  • 24. Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface.
    Abrahams KA, Cox JAG, Fütterer K, Rullas J, Ortega-Muro F, Loman NJ, Moynihan PJ, Pérez-Herrán E, Jiménez E, Esquivias J, Barros D, Ballell L, Alemparte C, Besra GS.
    Sci Rep; 2017 Aug 25; 7(1):9430. PubMed ID: 28842600
    [Abstract] [Full Text] [Related]

  • 25. In silico Screening of Food and Drug Administration-approved Compounds against Trehalose 2-sulfotransferase (Rv0295c) in Mycobacterium tuberculosis: Insights from Molecular Docking and Dynamics Simulations.
    Sharma D, Gautam S, Srivastava N, Bisht D.
    Int J Mycobacteriol; 2024 Jan 01; 13(1):73-82. PubMed ID: 38771283
    [Abstract] [Full Text] [Related]

  • 26. ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines.
    Saxena AK, Alam M.
    Curr Top Med Chem; 2020 Jan 01; 20(29):2723-2734. PubMed ID: 32885753
    [Abstract] [Full Text] [Related]

  • 27. Inhibitor binding studies of Mycobacterium tuberculosis MraY (Rv21 56c): Insights from molecular modeling, docking, and simulation studies.
    Mallavarapu BD, Abdullah M, Saxena S, Guruprasad L.
    J Biomol Struct Dyn; 2019 Sep 01; 37(14):3751-3763. PubMed ID: 30239262
    [Abstract] [Full Text] [Related]

  • 28. Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in Mycobacterium tuberculosis.
    Prabu A, Hassan S, Prabuseenivasan, Shainaba AS, Hanna LE, Kumar V.
    J Mol Graph Model; 2015 Sep 01; 61():133-40. PubMed ID: 26245695
    [Abstract] [Full Text] [Related]

  • 29. Discovery and evaluation of novel Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors as therapeutic drug leads.
    Krishna VS, Zheng S, Rekha EM, Guddat LW, Sriram D.
    J Comput Aided Mol Des; 2019 Mar 01; 33(3):357-366. PubMed ID: 30666485
    [Abstract] [Full Text] [Related]

  • 30. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
    Saxena S, Abdullah M, Sriram D, Guruprasad L.
    J Biomol Struct Dyn; 2018 Sep 01; 36(12):3184-3198. PubMed ID: 28948866
    [Abstract] [Full Text] [Related]

  • 31. Discovery of potent antimycobacterial agents targeting lumazine synthase (RibH) of Mycobacterium tuberculosis.
    Singh M, Dhanwal A, Verma A, Augustin L, Kumari N, Chakraborti S, Agarwal N, Sriram D, Dey RJ.
    Sci Rep; 2024 May 28; 14(1):12170. PubMed ID: 38806590
    [Abstract] [Full Text] [Related]

  • 32. Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs.
    Khare G, Kar R, Tyagi AK.
    PLoS One; 2011 May 28; 6(7):e22441. PubMed ID: 21818324
    [Abstract] [Full Text] [Related]

  • 33. Discovery of antimicrobial agent targeting tryptophan synthase.
    Bosken YK, Ai R, Hilario E, Ghosh RK, Dunn MF, Kan SH, Niks D, Zhou H, Ma W, Mueller LJ, Fan L, Chang CA.
    Protein Sci; 2022 Feb 28; 31(2):432-442. PubMed ID: 34767267
    [Abstract] [Full Text] [Related]

  • 34. Insight into the structural requirements of aminopyrimidine derivatives for good potency against both purified enzyme and whole cells of M. tuberculosis: combination of HQSAR, CoMSIA, and MD simulation studies.
    Punkvang A, Hannongbua S, Saparpakorn P, Pungpo P.
    J Biomol Struct Dyn; 2016 May 28; 34(5):1079-91. PubMed ID: 26156406
    [Abstract] [Full Text] [Related]

  • 35. High throughput screening of 7-methylpicene-1,2-diol as arylamine N-acetyltransferase (NAT) inhibitor to establish a isoniazid supplement in anti-tubercular therapy.
    Chowdhury A, Paul P, Choudhury MD.
    Comb Chem High Throughput Screen; 2013 Nov 28; 16(9):721-5. PubMed ID: 23701008
    [Abstract] [Full Text] [Related]

  • 36. A consensus reverse docking approach for identification of a competitive inhibitor of acetyltransferase enhanced intracellular survival protein from Mycobacterium tuberculosis.
    Santos-Júnior PFDS, Batista VM, Nascimento IJDS, Nunes IC, Silva LR, Costa CACB, Freitas JD, Quintans-Júnior LJ, Araújo-Júnior JX, Freitas MEG, Zhan P, Green KD, Garneau-Tsodikova S, Mendonça-Júnior FJB, Rodrigues-Junior VS, Silva-Júnior EFD.
    Bioorg Med Chem; 2024 Jun 15; 108():117774. PubMed ID: 38833750
    [Abstract] [Full Text] [Related]

  • 37. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H.
    Curr Pharm Des; 2014 Jun 15; 20(27):4305-6. PubMed ID: 24245755
    [Abstract] [Full Text] [Related]

  • 38. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
    Guardia A, Gulten G, Fernandez R, Gómez J, Wang F, Convery M, Blanco D, Martínez M, Pérez-Herrán E, Alonso M, Ortega F, Rullás J, Calvo D, Mata L, Young R, Sacchettini JC, Mendoza-Losana A, Remuiñán M, Ballell Pages L, Castro-Pichel J.
    ChemMedChem; 2016 Apr 05; 11(7):687-701. PubMed ID: 26934341
    [Abstract] [Full Text] [Related]

  • 39. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
    Akinpelu OI, Lawal MM, Kumalo HM, Mhlongo NN.
    Tuberculosis (Edinb); 2020 Mar 05; 121():101920. PubMed ID: 32279872
    [Abstract] [Full Text] [Related]

  • 40. New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis.
    Lupien A, Foo CS, Savina S, Vocat A, Piton J, Monakhova N, Benjak A, Lamprecht DA, Steyn AJC, Pethe K, Makarov VA, Cole ST.
    PLoS Pathog; 2020 Jan 05; 16(1):e1008270. PubMed ID: 31971990
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.